Search

everythinglearnresearchcommunity

for

Search:↓

Cronkhite-Canada syndrome can cause multiple gastrointestinal polyps and various physical symptoms.

There is no standard treatment for CCCA, and practices vary widely.

PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.

More research is needed on CCCA in children, especially Black and Asian adolescents.

A machine learning model called CATNIP can predict new uses for existing drugs, like using antidepressants for Parkinson's disease and a thyroid cancer drug for diabetes.

Removing β-catenin in certain stem cells causes hair whitening and pigmentation issues.

Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.

Semecarpus anacardium leaf extracts may offer safe, effective cancer treatment alternatives.

CCCA is a hair loss type affecting African women, possibly caused by grooming and chemicals, with various treatments and needing more research.

Mast cells may significantly contribute to central centrifugal cicatricial alopecia.

PROMETHEUS helps organize and evaluate causal claims from large language models.

CCCA involves immune response and metabolism issues, suggesting new treatment options.

Cronkhite-Canada syndrome is rare, has a poor prognosis, and requires early diagnosis and ongoing treatment.

Block and replace therapy improved symptoms in recurrent cyclic Cushing’s disease.

Activated β-catenin affects hair growth and skin thickness, and changes are reversible.

Basal cell carcinoma with matrical differentiation is a rare type linked to hair follicles, with .-catenin important for its development.

Most patients with Central Centrifugal Cicatricial Alopecia at the reviewed institution were middle-aged Black women, often with no symptoms, and commonly treated with topical medications.

CCCA may involve the PD1/PDL1 pathway and increased caspase 3, leading to permanent hair loss.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

CMC2.24 and CMC2.23 reduce melanin safely and effectively.

CCCA is a scarring hair disorder mainly affecting people of African descent, needing better awareness and treatment.

CCCA is a common, progressive hair loss condition that may not always be linked to hair care practices and requires a biopsy for diagnosis.

Cystatin M/E strongly inhibits cathepsin V and cathepsin L, important for skin formation.

The document concludes that inhalation of oxygen and sumatriptan injections are primary for cluster headaches, indomethacin for paroxysmal hemicrania, and lidocaine and lamotrigine for SUNCT, but SUNCT often resists treatment.

Introducing the OTC gene improved symptoms in mice with OTC deficiency.

The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.

Melatonin stops melanin production after tyrosinase action, with cyclic GMP mimicking this effect.

Cyclic nucleotide-gated channels are crucial for proper root hair growth and calcium balance in plants.

Diagnose and manage CCCA with thorough history, exams, and labs; treat with anti-inflammatory agents, stress reduction, and stopping harmful hair practices.

CCCA is a common, scarring hair loss in Black women that needs early detection.